Study of SIM0508 Alone and in Combination in Patients With Advanced Solid Tumors
This is a multicenter, open-label, first-in-human study to evaluate the safety,efficacy, and PK/PD characteristics of SIM0508 as a single agent and in combination with olaparib in participants with locally advanced/metastatic solid tumors.
Advanced Solid Tumors
DRUG: SIM0508 Tablets|DRUG: SIM0508 in combination with olaparib|DRUG: SIM0508 in combination with olaparib
Dose-limiting toxicity (DLT), Primary Endpoints, At the end of Cycle 1 (each cycle is 28 days)
This is a multicenter, open-label, first-in-human study to evaluate the safety,efficacy, and PK/PD characteristics of SIM0508 as a single agent and in combination with olaparib in participants with locally advanced/metastatic solid tumors.